Investigator to Congress: Ketek data was known to be fraudulent

Share this content:

A subpoenaed FDA criminal investigator has told Congress that Aventis should have known that data it submitted to support the approval of antibiotic Ketek was fraudulent. Agent Douglas Loveland testified that there were so many “red flags” in one study that the company should have notified the FDA. 

Share this content:
Scroll down to see the next article